N-(7-chloro-2.3-dihydro-2-methyl-5-nitro-1H-isoindol-4-yl)acetamide | 156694-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(7-chloro-2.3-dihydro-2-methyl-5-nitro-1H-isoindol-4-yl)acetamide
• 英文别名: N-(7-chloro-2-methyl-5-nitro-1,3-dihydroisoindol-4-yl)acetamide
• CAS: 156694-57-4
• 化学式: C₁₁H₁₂ClN₃O₃
• 分子量: 269.688
• InChiKey: ZVEYSGXQJZTSRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  78.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE
  申请人：——

  公开号：US20030114422A1

  公开（公告）日：2003-06-19

  A compound having the formula 1 or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R 1 is hydrogen, alkyl, arylalkyl, (CH 2 ) n OH, or (CH 2 ) NR 7 R 8 ; R 5 and R 6 are each independently hydrogen, halogen, NO 2 , CN, CF 3 , SO 2 NR 7 R 8 , PO 3 R 9 R 10 , alkyl, alkenyl, alkynyl, (CH 2 ) n CONR 7 R 8 , (CH 2 ) n CO 2 R 10 , NHCOR 11 , wherein R 7 and R 8 are each independently hydrogen or alkyl or together R 7 and R 8 form a ring of from three to seven atoms, R 9 is hydrogen or alkyl, R 10 is hydrogen or alkyl, R 11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR 12 —CHR 13 —CHR 14 -b, a-CHR 13 —CHR 14 —NR 12 -b, a-CHR 13 —NR 12 —CHR 14 -b, a-CHR 14 —CH 2 —NR 12 —CHR 13 -b, a-CHR 13 —NR 12 —CH 2 —CHR 14 -b, a-CH 2 —CH 2 —CHR 13 —NR 12 -b, a-NR 12 —CHR 12 —CHR 13 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —NR 12 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —CH 2 NR 12 —CH 2 -b, a-CH 2 —NR 12 —CH 2 —CH 2 -b a-CH 2 —CH 2 —CH 2 —CH 2 —NR 12 -b, a-NR 12 —CH 2 —CH 2 —CH 2 —CH 2 -b, wherein R 12 is hydrogen, CH 2 CH 2 OH, or alkyl, and R 13 and R 14 are each independently hydrogen, CN, CONH 2 , CH 2 NH 2 , CH 2 OH, alkyl, arylalkyl, alkenyl, or CO 2 R 15 , wherein R 15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.

  具有以下式1的化合物或其药学上可接受的盐，其中R为氢或羟基；R1为氢、烷基、芳基烷基、(CH2)nOH或( )NR7R8；R5和R6各自独立地为氢、卤素、NO2、CN、CF3、SO2NR7R8、PO3R9R10、烷基、烯基、炔基、( )nCONR7R8、( )nCO2R10、NHCOR11，其中R7和R8各自独立地为氢或烷基，或者一起形成由三至七个原子组成的环的R7和R8；R9为氢或烷基，R10为氢或烷基，R11为氢或烷基，n为从零到四的整数；A为与苯环在标记为a和b的位置融合的五至七个原子组成的环，并由以下二价基团形成：a-NR12—CHR13—CHR14-b，a-CHR13—CHR14—NR12-b，a-CHR13—NR12—CHR14-b，a-CHR14— —NR12—CHR13-b，a-CHR13—NR12— —CHR14-b，a- — —CHR13—NR12-b，a-NR12—CHR12—CHR13— — -b，a- — —NR12— — -b，a- — — NR12— -b，a- —NR12— — -b，a- — — — —NR12-b，a-NR12— — — — -b，其中R12为氢、 OH或烷基，R13和R14各自独立地为氢、CN、CONH2、 NH2、 OH、烷基、芳基烷基、烯基或CO2R15，其中R15为氢或烷基。这些化合物在治疗对谷氨酸和天冬氨酸受体阻滞有反应的哺乳动物的疾病中有用。还包括用于制备这些化合物的方法和在这些方法中有用的新中间体。
• QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0664807B1

  公开（公告）日：1997-09-10
• US6703391B2
  申请人：——

  公开号：US6703391B2

  公开（公告）日：2004-03-09
• [EN] QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS<br/>[FR] DERIVES DE QUINOXALINEDIONE UTILES COMME ANTAGONISTES D'ACIDES AMINES EXCITATEURS
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1994009000A1

  公开（公告）日：1994-04-28

  (EN) A compound having formula (I) or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or hydroxy; R1 is hydrogen, alkyl, arylalkyl, (CH2)nOH or (CH2)nNR7R8; R5 and R6 are each independently hydrogen, halogen, NO2, CN, CF3, SO2NR7R8, PO3R9R10, alkyl, alkenyl, alkynyl, (CH2)nCONR7R8, (CH2)nCO2R10, NHCOR11, wherein R7 and R8 are each independently hydrogen or alkyl or together R7 and R8 form a ring of from three to seven atoms, R9 is hydrogen or alkyl, R10 is hydrogen or alkyl, R11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR12-CHR13-CHR14-b, a-CHR13-CHR14-NR12-b, a-CHR13-NR12-CHR14-b, a-CHR14-CH2-NR12-CHR13-b, a-CHR13-NR12-CH2-CHR14-b, a-CH2-CH2-CHR13-NR12-b, a-NR12-CHR13-CH2-CH2-b, a-CH2-CH2-NR12-CH2-CH2-b, a-CH2-CH2-CH2-NR12-CH2-b, a-CH2-NR12-CH2-CH2-CH2-b, a-CH2-CH2-CH2-CH2-NR12-b, a-NR12-CH2-CH2-CH2-CH2-b, wherein R12 is hydrogen, CH2CH2OH, or alkyl, and R13 and R14 are each independently hydrogen, CN, CONH2, CH2NH2, CH2OH, alkyl, arylalkyl, alkenyl or CO2R15, wherein R15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.(FR) Un composé a la formule (I), dans laquelle R désigne hydrogène ou hydroxyle; R1 désigne hydrogène, alkyle, arylalkyle (CH2)nOH ou (CH2)nNR7R8; R5 et R6 désignent indépendamment l'un de l'autre hydrogène, halogène, NO2, CN, CF3, SO2NR7R8, PO3R9R10, alkyle, alcényle, alcynyle, (CH2)nCONR7R8, (CH2)nCO2R10, NHCOR11, où R7 et R8 désignent indépendamment l'un de l'autre hydrogène ou alkyle, ou R7 et R8 forment ensemble un cycle ayant trois à sept atomes; R9 désigne hydrogène ou alkyle; R10 désigne hydrogène ou alkyle; R11 désigne hydrogène ou alkyle; et n est un nombre entier compris entre zéro et quatre; A désigne un cycle ayant cinq à sept atomes fusionné avec le cycle benzénique aux positions indiquées par a et b, formé par les radicaux bivalents suivants: a-NR12-CHR13-CHR14-b, a-CHR13-CHR14-NR12-b, a-CHR13-NR12-CHR14-b, a-CHR14-CH2-NR12-CHR13-b, a-CHR13-NR12-CH2-CHR14-b, a-CH2-CH2-CHR13-NR12-b, a-NR12-CHR13-CH2-CH2-b, a-CH2-CH2-NR12-CH2-CH2-b, a-CH2-CH2-CH2-NR12-CH2-b, a-CH2-NR12-CH2-CH2-CH2-b, a-CH2-CH2-CH2-CH2-NR12-b, a-NR12-CH2-CH2-CH2-CH2-b, dans lesquels R12 désigne hydrogène, CH2CH2OH ou alkyle, et R13 et R14 désignent, indépendamment l'un de l'autre, hydrogène, CN, CONH2CH2NH2, CH2OH, alkyle, arylalkyle, alcényle ou CO2R15, où R15 désigne hydrogène ou alkyle. Ces composés ou leurs sels pharmaceutiquement admissibles sont utiles pour traiter des troubles de la santé de mammifères qui réagissent au blocage des récepteurs des acides glutamique et aspartique. L'invention concerne également des procédés de préparation de ces composés et des produits intermédiaires nouveaux utiles pour mettre en ÷uvre ces procédés.